Drug Trial Radar · NCT06462365
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Last checked: Nov 19, 2026Latest source record: Apr 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Apr 8, 2024
Primary completion
Apr 15, 2026
Study completion Apr 15, 2027
Sponsor
- Lead sponsor
- Tr1X, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.
Conditions
- Hematologic Malignancy
- GvHD
- GVHD,Acute
- GVHD, Chronic
- Hematopoietic Stem Cell Transplant
- Acute Lymphoblastic Leukemia, Adult B-Cell
- Acute Lymphoblastic Leukemia, Adult T-Cell
- Acute Myeloid Leukemia in Remission
- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia, in Remission
- Cancer Remission
Interventions
TRX103Biological
TRX103 infusion via central line.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of TRX103 cell infusion through incidence of Adverse events.Time frame: Up to a year
- Safety of TRX103 determined by stem cell engraftment and donor chimerism after HSCT measured by absolute neutrophil counts and percent donor chimerism.Time frame: Up to day 42
- Safety of TRX103 determined by negative Replication Competent Lentivirus (RCL).Time frame: At 3-month, 6-month, and 1-year.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.